Campbell & CO Investment Adviser LLC Has $174,000 Holdings in MannKind Corporation $MNKD

Campbell & CO Investment Adviser LLC raised its holdings in MannKind Corporation (NASDAQ:MNKD) by 202.2% in the second quarter, Holdings Channel reports. The fund owned 46,407 shares of the biopharmaceutical company’s stock after acquiring an additional 31,051 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in MannKind were worth $174,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of MannKind in the 2nd quarter valued at approximately $254,000. Los Angeles Capital Management LLC lifted its stake in MannKind by 68.3% in the second quarter. Los Angeles Capital Management LLC now owns 437,316 shares of the biopharmaceutical company’s stock valued at $1,636,000 after buying an additional 177,440 shares in the last quarter. Simon Quick Advisors LLC bought a new position in MannKind in the second quarter valued at approximately $180,000. Quaker Wealth Management LLC boosted its holdings in shares of MannKind by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 14,000 shares during the period. Finally, Teacher Retirement System of Texas increased its position in shares of MannKind by 4.7% during the second quarter. Teacher Retirement System of Texas now owns 77,726 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 3,506 shares in the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

Insider Buying and Selling at MannKind

In related news, insider Stuart A. Tross sold 47,000 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $5.34, for a total transaction of $250,980.00. Following the transaction, the insider directly owned 1,032,013 shares in the company, valued at approximately $5,510,949.42. The trade was a 4.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sanjay R. Singh sold 18,777 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $5.03, for a total transaction of $94,448.31. Following the sale, the executive vice president directly owned 455,211 shares in the company, valued at $2,289,711.33. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.70% of the stock is currently owned by company insiders.

MannKind Stock Performance

NASDAQ:MNKD opened at $5.06 on Wednesday. The stock’s 50-day simple moving average is $5.41 and its 200 day simple moving average is $4.58. MannKind Corporation has a 52-week low of $3.38 and a 52-week high of $7.07. The company has a market cap of $1.55 billion, a P/E ratio of 46.00 and a beta of 1.11.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. The firm had revenue of $82.13 million during the quarter, compared to the consensus estimate of $80.47 million. MannKind had a negative return on equity of 32.60% and a net margin of 10.87%.The business’s revenue was up 17.1% compared to the same quarter last year. During the same period last year, the company earned $0.04 earnings per share. As a group, equities analysts predict that MannKind Corporation will post 0.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Oppenheimer boosted their price objective on shares of MannKind from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Royal Bank Of Canada cut their price target on MannKind from $8.00 to $7.50 and set an “outperform” rating on the stock in a report on Tuesday, November 11th. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a report on Monday, October 6th. Wells Fargo & Company dropped their target price on MannKind from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Finally, Wall Street Zen raised MannKind from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.21.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.